Manager TitleAgeSince
President - 29/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
-0.13%-6.44%+60.47%+112.05% 1,047B
+0.85%-0.81%+52.77%+63.15% 646B
-1.03%-3.58%+22.87%+73.29% 451B
-1.46%-4.50%+37.43%+38.41% 355B
-0.72%-2.89%+21.86%+36.79% 291B
-1.19%-2.21%+1.35%+12.29% 252B
-1.05%-1.57%+51.40%+68.55% 234B
+0.08%-1.78%-17.64%-54.29% 203B
-2.14%-0.30%+29.42%+89.10% 181B
Average -0.48%-2.68%+28.88%+48.82% 406.59B
Weighted average by Cap. -0.48%-3.46%+38.66%+65.51%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock